Impact of biologic initiation on steroid burden and new-onset of potentially OCS-related outcomes in patients with severe asthma (SOLAR)

Study identification

• EU PAS number:
  EUPAS104139
• Study ID:
  104140
• Official title and acronym:
  Impact of biologic initiation on steroid burden and new-onset of potentially OCS-related outcomes in patients with severe asthma (SOLAR)
• DARWIN EU® study:
  No
• Study countries:
  Argentina

  Australia

  Bulgaria

  Canada

  Colombia

  Denmark

  Greece

  Hungary

  India

  Ireland

  Italy

  Japan

  Korea, Republic of

  Kuwait

  Mexico

  Poland

  Portugal

  Saudi Arabia

  Singapore

  Spain

  Taiwan

  United Arab Emirates

  United Kingdom

  United States
• Study status:
  Planned

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Study timelines

Date when funding contract was signed

Planned:03/10/2022

Study start date

Planned:02/01/2023

Date of interim report, if expected

Planned:01/05/2023

Date of final study report

Planned:31/03/2024

Sources of funding

Other

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, OPRI Pte Ltd

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable